Less Ads, More Data, More Tools Register for FREE

Pin to quick picksUnicorn Asset Management Regulatory News (UAV)

Share Price Information for Unicorn Asset Management (UAV)

Share Price is delayed by 15 minutes
Get Live Data
70.00    0.00 (0.00%)
Bid:
67.00
Ask:
73.00
Spread: 6.00 (8.955%)
Market Cap: £180.27m
UAV Live PriceLast checked at - London Stock Exchange

Intraday Unicorn Asset Management Share Chart

Interim Management Statement

23 Jul 2020 12:51

RNS Number : 9204T
Unicorn AIM VCT PLC
23 July 2020
 

Unicorn AIM VCT plc ("the Company")

LEI: 21380057QDV7D34E9870

Interim Management Statement 

For the period from 1 April 2020 to 30 June 2020

 

Introduction

 

This voluntary Interim Management Statement (IMS) covers the three month period ended 30 June 2020, together with relevant information up to the date of publication. 

 

Investment Objective

 

The Company's objective is to provide Shareholders with an attractive return from a diversified portfolio of investments, predominantly in the shares of AIM quoted companies, by maintaining a steady flow of dividend distributions to Shareholders from the income as well as capital gains generated by the portfolio.

 

It is also the objective that the Company should continue to qualify as a Venture Capital Trust ("VCT"), so that Shareholders benefit from the taxation advantages that this brings. To achieve this, at least 80% of the Company's total assets are to be invested in qualifying investments of which 70% by VCT value (30% in respect of investments made before 6 April 2018 from funds raised before 6 April 2011) must be in ordinary shares, which carry no preferential rights (save as permitted under VCT rules) to dividends or return of capital and no rights to redemption.

 

Performance

 

Net asset value per share recovered strongly in the period under review, as equity markets rallied following the steep declines triggered by the spread of the COVID-19 pandemic.

As at 30 June 2020, the unaudited net asset value was 159.2 pence per share, which represents an increase of 24.0% on the unaudited closing net asset value of 128.4 pence per share as at 31 March 2020. By comparison, the FTSE AIM All-Share Index generated a total return of +29.7%, while the FTSE All-Share Index delivered a total return of 10.2% over the same period.

The performance of the Company's diverse portfolio of investments, has been largely resilient throughout the rapidly evolving Covid-19 crisis. It is encouraging to report that a number of our investee companies have been actively engaged in helping to combat the worst impacts of the pandemic. Businesses such as Abcam, Avacta, Genedrive, Omega Diagnostics and Tristel are all currently working to help ease the negative effects of the virus; either by helping to find a cure, developing testing kits or by providing disinfectant solutions to the healthcare sector. The Company has limited exposure to businesses dependent upon consumer spending, which has insulated Shareholders from the worst of the equity market falls experienced during the earlier part of 2020.

The portfolio remains predominantly composed of investments in businesses listed on the Alternative Investment Market (AIM). Many of these investee companies are relatively mature and, typically have remained profitable throughout the difficulties experienced since the start of 2020.

Deal flow has begun to improve as the period of strict lockdown appears to be reaching an end. Importantly, the rate of new investment required to meet all key HMRC tests has also been maintained. Following the recent closure of the fully subscribed Offer for Subscription, we have substantial cash available to deploy in the investment opportunities that pass the thorough due diligence process. It is important however, to remind Shareholders and potential new investors in the Company, that the new capital raised will, by regulatory necessity, be targeted at younger, less well-established businesses. Early stage, scale-up businesses tend to be loss-making and therefore more risky in investment terms. Our focus on providing scale-up capital has become even more important and relevant to early-stage businesses during the current crisis, however it should be noted that, despite the improved availability of State-aided capital, not all of them will be successful.

Despite the increased risks associated with early stage investment and the uncertainty created by the unexpected onset of a worldwide pandemic, the Investment Manager is confident that the portfolio, as a whole, offers the prospect of delivering attractive total returns over the longer term.

At the period end, an estimated 88% of total assets (by VCT value and excluding new capital) were invested in VCT qualifying companies.

Material Transactions

During the period under review, 2 follow-on VCT qualifying investments were made at a total cost of £0.5 million. In addition, subsequent to the period end, one new VCT qualifying investment, amounting to £2.0 million, was completed.

In aggregate, approximately £2.6 million was raised from the partial disposal of 4 holdings during the period. The usual purpose of such disposals is threefold; to ensure stock specific risk is contained, to lock in capital profits for future distribution to Shareholders via dividend payments and to help manage liquidity requirements. In addition, one holding was sold in its entirety as a result of M&A activity, realising proceeds of £1.9 million and crystallising a capital profit on disposal of £1.4 million.

Top Ten Holdings as at 30 June 2020

Stock

% of net assets

Interactive Investor

8.7%

Hasgrove plc

7.0%

Abcam

7.0%

Tracsis plc

4.4%

Tristel plc

2.9%

Anpario

2.9%

Mattioli Woods plc

2.9%

Renalytix AI

2.7%

Cohort plc

2.6%

MaxCyte Inc

2.4%

Total

43.5%

 

Share Buy-Backs

 

During the period from 1 April 2020 to 30 June 2020, the Company bought back 447,110 of its own Ordinary Shares for cancellation, at an average price of 110.0 pence per share. As at 30 June 2020, there were 147,391,486 Ordinary Shares in issue. After the period end, a further 631,281 Ordinary Shares were purchased for cancellation at a price of 129.5 pence per share.

 

Dividends

As previously advised, the Board declared an interim dividend of 3.0 pence per share in respect of the Company's half-year ended 31 March 2020. This interim dividend will be paid on 12 August 2020 to Shareholders who were on the register on 17 July 2020.

Material Events

The Offer for Subscription was fully subscribed and closed on 11 June 2020, having raised £24.2 million net of expenses. There were no other material events during the period from 1 April 2020 to 30 June 2020.

 

Chris Hutchinson

Unicorn Asset Management

Investment Manager

 

23 July 2020

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRDZGZNMFRGGZM
Date   Source Headline
1st Apr 202510:07 amRNSTotal Voting Rights
31st Mar 202511:15 amRNSOffer for Subscription - Update
18th Mar 20257:00 amRNSTransaction in Own Shares
12th Mar 202512:04 pmRNSOffer Update - Overallotment
11th Mar 20251:01 pmRNSDirector/PDMR Shareholding
11th Mar 202511:15 amRNSIssue of Equity under Offer
6th Mar 202511:14 amRNSNet Asset Value(s)
3rd Mar 202510:05 amRNSTotal Voting Rights
21st Feb 20257:00 amRNSDirector/PDMR Shareholding
21st Feb 20257:00 amRNSIssue of Equity
12th Feb 20251:27 pmRNSResult of AGM
4th Feb 20252:39 pmRNSNet Asset Value(s)
3rd Feb 202510:15 amRNSTotal Voting Rights
28th Jan 202512:14 pmRNSPublication of a Prospectus
17th Jan 20256:01 pmRNSTransaction in Own Shares
10th Jan 20253:31 pmRNSNet Asset Value(s)
2nd Jan 202512:51 pmRNSDirector Declaration
2nd Jan 20257:00 amRNSTotal Voting Rights
17th Dec 20244:18 pmRNSTransaction in Own Shares
9th Dec 20242:17 pmRNSNet Asset Value(s)
6th Dec 20247:00 amRNSFinal Results
29th Nov 202411:59 amRNSDividend Declaration
27th Nov 20247:00 amRNSINTENTION TO LAUNCH AN OFFER
5th Nov 20243:05 pmRNSNet Asset Value(s)
18th Oct 202411:05 amRNSNet Asset Value(s)
2nd Oct 202410:30 amRNSDirectorate Change
1st Oct 20249:45 amRNSTotal Voting Rights
18th Sep 20247:00 amRNSTransaction in Own Shares
9th Sep 20249:56 amRNSNet Asset Value(s)
2nd Sep 202410:02 amRNSTotal Voting Rights
16th Aug 20248:58 amRNSTransaction in Own Shares
13th Aug 20249:38 amRNSDirector/PDMR Shareholding
13th Aug 20249:16 amRNSIssue of Equity
6th Aug 20249:31 amRNSNet Asset Value(s)
8th Jul 20242:00 pmRNSNet Asset Value(s)
1st Jul 202410:12 amRNSTotal Voting Rights
20th Jun 20242:25 pmRNSTransaction in Own Shares
7th Jun 20247:00 amRNSNet Asset Value(s)
23rd May 20247:00 amRNSHalf-year Report
8th May 20249:47 amRNSNet Asset Value(s)
8th Apr 20241:46 pmRNSNet Asset Value(s)
2nd Apr 202410:46 amRNSTotal Voting Rights
18th Mar 20247:00 amRNSTransaction in Own Shares
11th Mar 202412:00 pmRNSDirector/PDMR Shareholding
11th Mar 202411:59 amRNSTotal Voting Rights
11th Mar 202411:57 amRNSIssue of Equity
7th Mar 202411:34 amRNSNet Asset Value(s)
1st Mar 202410:54 amRNSTotal Voting Rights
15th Feb 20244:30 pmRNSOffer for Subscription Update
14th Feb 20241:36 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.